12:00 AM
 | 
Aug 22, 2011
 |  BC Week In Review  |  Company News  |  Deals

Endo, Gruenenthal deal

Endo ended a 2009 deal with Gruenenthal under which the biotech had exclusive rights to develop and commercialize Gruenenthal's axomadol in the U.S. and Canada. In late...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >